Print Page  Close Window

Investor Relations
Corporate Profile

We are Zogenix.

Zogenix is committed to developing therapies that address specific clinical needs for people living with CNS and pain-related conditions who need innovative treatment alternatives to help them return to normal daily functioning.

A significant number of patients are not being effectively treated, despite the availability of current therapies. These patients deserve access to safe and effective treatments. Zogenix is committed to ensuring the safe and appropriate use of our products ... More >>

Latest PresentationsMore >>
Title
Download Documentation Zogenix October 2014 Investor Presentation
Get help downloading or viewing the above file types
Stock Quote
ZGNX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.26
Change (%) Stock is Down 0.06 (4.55%)
Volume1,074,957
Data as of 10/22/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
10/01/14Zogenix Submits Modified Formulation of Zohydro(R) ER With Potential Abuse Deterrent Properties for FDA Review
SAN DIEGO, Oct. 1, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it has submitted to the U.S. Food and Drug Administration (FDA) a supplemental New Drug Application (sNDA) for a modified formulation of Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII, which has been designed to have abuse deterrent properties. The... 
Printer Friendly Version
09/18/14New Data Shows Zohydro(R) ER Reduced Pain and Improved Function in People With Chronic Pain
Moderate and Substantial Levels of Pain Relief Produce the Greatest Functional Benefits With Zohydro(R) ER (hydrocodone bitartrate) Extended-Release Capsules, CII PHOENIX, Sept. 18, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today presented data from a one year open label study that demonstrated chronic pain patients who achieved substantial l... 
Printer Friendly Version
09/04/14Education, Patient-Focused Approach to Treating Chronic Pain Are Keys to Preventing Opioid Abuse, Say Experts, Patients
Patients Want Access to a Full Range of FDA-Approved Medications and Pain Relief That Lasts for the Duration of the Prescribed Dosing SAN DIEGO, Sept. 4, 2014 (GLOBE NEWSWIRE) -- When leading health care professionals, chronic pain patients and pain community advocates gathered recently to kick off National Pain Awareness Month, their discussions quickly turned to the challenge of balancing public health concerns about opioid abuse and the unmet medical needs of millions of Americans whose dail... 
Printer Friendly Version
09/02/14Zohydro(R) ER Demonstrates Sustained 12-Hour Pain Relief
No Additional Nighttime Dosing and No End-of-Dose Failure, in Most Patients, According to Post-Hoc Analysis Presented at PAINWeek SAN DIEGO, Sept. 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced new post-hoc analysis data showing that the indicated 12-hour dose of Zohydro® ER, (hydrocodone bitartrate) Extended-Release Capsules, C... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.